Mesoblast Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MEOBF | SLDB | 7776.T | 4880.T | LCTX | RXRX | |
|---|---|---|---|---|---|---|
| Market cap | 1.71B | 699.11M | 6.78B | 5.76B | 260.49M | 2.42B |
| P/E (TTM) | — | — | — | 58.4 | — | — |
| Forward P/E | — | -3.8 | — | 16.1 | -7.5 | -4.5 |
| Price/book | 3.0 | 2.9 | 3.0 | 1.0 | 4.3 | 2.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −2.22% | +54.69% | −57.71% | −42.83% | −40.46% | −16.02% |
| Today | 0.00% | +3.82% | −4.97% | +3.94% | +1.98% | +5.43% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All MEOBF news ›MESO: SEC Form 6-K filed by Mesoblast Limited
Plus members following MESO get this by push and email as soon as it reaches us. Written by Quantisnow AI from this filing. Not financial advice. No. The form only lists and attaches the two exhibits and does not summarize their contents.…
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and…
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004…
Mesoblast (OTCMKTS:MEOBF) Stock Falls 13.9% – Here’s What Happened
Posted by Kim Johansen on Nov 5th, 2026 Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report)’s stock price was down 13.9% during mid-day trading on Wednesday. The company traded as low as $1.14 and last traded at $1.14. 500 shares were…
Mesoblast highlights Ryoncil as first-line treatment after steroids for pediatric acute graft-versus-host disease
Mesoblast Limited hosted a webinar featuring Dr. Susan Prockop discussing Ryoncil (remestemcel-L-rknd) as a new treatment approach for pediatric acute graft-versus-host disease (aGvHD), used after steroids. Ryoncil is the first…
Mesoblast Stock Jumps 17% on Nasdaq as Ryoncil Sales Climb 44% and Cash Burn Collapses in Quarterly Update
Mesoblast shares jumped more than 17% on the Nasdaq in early trading Thursday. U.S. investors joined a rally in Australia after the cell therapy company reported strong growth in sales of its flagship drug Ryoncil and a sharp drop in cash…
Should I buy Cochlear and Mesoblast shares with $5,000?
These two companies are at different stages of their growth journeys. Here's which I'd choose for a long-term investment. Her work focuses on making complex financial ideas clear, practical, and engaging for everyday investors. She has a…
Why are Mesoblast shares racing 15% higher today?
Find out what caught investor interest. Samantha Menzies is a writer and editor with close to 20 years' experience covering finance, investing, business and property in Australia and the UK. She has held senior editorial roles at Yahoo…
Mesoblast Shares At The Foot of ASX 200 Today, In Lowest Close Of The Year
Mesoblast shares (ASX:MSB) fell sharply today, as markets continue to work through its preliminary first-quarter results. The Mesoblast share price closed out the opening trading session of the week down 11.06% at A$1.77, their lowest…
Mesoblast Shares Bounce Back From Lows To Lead ASX 200 Today
Mesoblast shares (ASX: MSB) put up a solid recovery today, with the stock climbing 5.68% to close at A$1.86, fresh off 52-week lows of A$1.74. Today’s ASX 200 leading performance will be welcome news for holders who have seen shares tumble…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- fool.com.au5
- kalkinemedia.com4
- stocktitan.net3
- thebull.com.au2
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.